file1,
file2, etc. all in the same folder or directory;
first, locate one of the files with the [Browse...] button. Then alter the
file path in the box above to include '*' character (eg. file*).
Wildcard '?' to blanket only one character works too.| Historiographs |
Grand Totals: LCS 121, GCS 3531, CR 4288 Collection span: 1979 - 2009 | |
| Word(i) List (760) Word count: 2047, All words count: 2852 | ||
| # | Word | Recs | TLCS | TGCS |
|---|---|---|---|---|
| 1 | PROSTATE | 91 | 68 | 1943 |
| 2 | CANCER | 73 | 60 | 1606 |
| 3 | CARCINOMA | 35 | 29 | 912 |
| 4 | BLADDER | 31 | 25 | 481 |
| 5 | PATIENTS | 20 | 21 | 677 |
| 6 | DETECTION | 17 | 18 | 595 |
| 7 | CELLS | 10 | 17 | 295 |
| 8 | THERAPY | 24 | 17 | 320 |
| 9 | HIGH | 9 | 16 | 188 |
| 10 | CELL | 22 | 15 | 509 |
| 11 | CONTRAST | 18 | 14 | 198 |
| 12 | ENHANCED | 16 | 14 | 338 |
| 13 | DOPPLER | 13 | 13 | 112 |
| 14 | RADIATION | 15 | 13 | 248 |
| 15 | PROSTATECTOMY | 21 | 12 | 236 |
| 16 | ANTIGEN | 8 | 11 | 234 |
| 17 | EFFECT | 12 | 11 | 197 |
| 18 | IMAGING | 15 | 11 | 150 |
| 19 | SPECIFIC | 8 | 11 | 234 |
| 20 | TRANSITIONAL | 8 | 11 | 111 |
| 21 | DISEASE | 4 | 9 | 107 |
| 22 | MANAGEMENT | 6 | 9 | 117 |
| 23 | ADJUVANT | 6 | 8 | 134 |
| 24 | EARLY | 4 | 8 | 136 |
| 25 | HEMATOGENOUS | 2 | 8 | 329 |
| 26 | RADICAL | 15 | 8 | 192 |
| 27 | BIOCHEMICAL | 3 | 7 | 87 |
| 28 | CONTROL | 3 | 7 | 87 |
| 29 | FREQUENCY | 4 | 7 | 40 |
| 30 | INVASION | 4 | 7 | 63 |
| # | Word | Recs | TLCS | TGCS |
| 31 | LAPAROSCOPY | 4 | 7 | 91 |
| 32 | MICROMETASTASIS | 1 | 7 | 292 |
| 33 | SONOGRAPHY | 7 | 7 | 96 |
| 34 | BEHAVIOR | 1 | 6 | 50 |
| 35 | BIOLOGIC | 3 | 6 | 84 |
| 36 | CHAIN | 3 | 6 | 205 |
| 37 | COLOR | 6 | 6 | 62 |
| 38 | CORRELATION | 3 | 6 | 50 |
| 39 | FHIT | 5 | 6 | 57 |
| 40 | FREE | 1 | 6 | 50 |
| 41 | GENE | 8 | 6 | 180 |
| 42 | LAPAROSCOPIC | 26 | 6 | 168 |
| 43 | POLYMERASE | 3 | 6 | 205 |
| 44 | PREDICTING | 1 | 6 | 50 |
| 45 | REACTION | 3 | 6 | 205 |
| 46 | REVERSE | 2 | 6 | 105 |
| 47 | SURVIVAL | 3 | 6 | 93 |
| 48 | TRIAL | 11 | 6 | 350 |
| 49 | ANALYSIS | 14 | 5 | 125 |
| 50 | EFFICACY | 4 | 5 | 108 |
| 51 | EXPERIENCE | 3 | 5 | 49 |
| 52 | FEZ1 | 3 | 5 | 18 |
| 53 | GRADE | 2 | 5 | 18 |
| 54 | INITIAL | 3 | 5 | 44 |
| 55 | LZTS1 | 2 | 5 | 18 |
| 56 | PATHOLOGIC | 4 | 5 | 74 |
| 57 | PATIENT | 4 | 5 | 83 |
| 58 | PT3N0 | 3 | 5 | 114 |
| 59 | REGULATED | 1 | 5 | 18 |
| 60 | RESTORATION | 1 | 5 | 18 |
| # | Word | Recs | TLCS | TGCS |
| 61 | SUPPRESSES | 1 | 5 | 18 |
| 62 | SURGERY | 6 | 5 | 81 |
| 63 | TRANSCRIPTASE | 1 | 5 | 75 |
| 64 | TUMORIGENICITY | 1 | 5 | 18 |
| 65 | CHEMOPREVENTION | 3 | 4 | 108 |
| 66 | DEVELOPMENT | 4 | 4 | 88 |
| 67 | DOSE | 6 | 4 | 117 |
| 68 | DUTASTERIDE | 6 | 4 | 126 |
| 69 | HISTORY | 1 | 4 | 6 |
| 70 | INTRAVESICAL | 5 | 4 | 115 |
| 71 | METASTATIC | 8 | 4 | 467 |
| 72 | PERSPECTIVE | 3 | 4 | 80 |
| 73 | POSITION | 1 | 4 | 14 |
| 74 | REDUCE | 4 | 4 | 108 |
| 75 | RENAL | 14 | 4 | 390 |
| 76 | RISK | 5 | 4 | 142 |
| 77 | SEMINAL | 3 | 4 | 50 |
| 78 | STATUS | 4 | 4 | 66 |
| 79 | UROLOGYS | 1 | 4 | 6 |
| 80 | VESICLE | 3 | 4 | 50 |
| 81 | ACTIVATION | 1 | 3 | 13 |
| 82 | ASSESSMENT | 7 | 3 | 128 |
| 83 | BCG | 2 | 3 | 88 |
| 84 | BENIGN | 5 | 3 | 79 |
| 85 | CD4 | 1 | 3 | 52 |
| 86 | CIRCULATING | 3 | 3 | 120 |
| 87 | COMPARISON | 7 | 3 | 103 |
| 88 | COMPLEX | 1 | 3 | 13 |
| 89 | DESIGN | 2 | 3 | 104 |
| 90 | DIAGNOSIS | 5 | 3 | 38 |
| # | Word | Recs | TLCS | TGCS |
| 91 | ERK | 1 | 3 | 13 |
| 92 | ERK1 | 1 | 3 | 13 |
| 93 | EVENTS | 3 | 3 | 104 |
| 94 | EXPRESSION | 3 | 3 | 260 |
| 95 | FAK | 1 | 3 | 13 |
| 96 | FAVORS | 2 | 3 | 16 |
| 97 | FORMATION | 1 | 3 | 13 |
| 98 | INACTIVATION | 2 | 3 | 16 |
| 99 | INTERLEUKIN | 4 | 3 | 63 |
| 100 | LOSS | 3 | 3 | 54 |